Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

INTRODUCTION: This study outlined cemiplimab intravenous (IV) dosing strategy to move from body weight (BW)-based 3 mg/kg every-2-week (Q2W) dosing in first-in-human study (study 1423; NCT02383212) to fixed 350 mg every-3-week (Q3W) dosing, utilizing population pharmacokinetics (PopPK) modeling and...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Adv Ther
मुख्य लेखकों: Paccaly, Anne J., Migden, Michael R., Papadopoulos, Kyriakos P., Yang, Feng, Davis, John D., Rippley, Ronda K., Lowy, Israel, Fury, Matthew G., Stankevich, Elizabeth, Rischin, Danny
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer Healthcare 2021
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107152/
https://ncbi.nlm.nih.gov/pubmed/33768419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01638-5
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन